I agree that low grade, stage I, 'rare, less aggressive' histology has a great prognosis vis-a-vis distant metastasis. But, my decision on adjuvant endocrine therapy will not be based on just the histologic subtype. In other words, I would factor in traditional prognostic factors in deciding therape...

There are clearly some patients with small tumor and favorable biology who don't benefit much from any adjuvant therapy. It has been hard to identify such patients but Mammaprint testing may help as they identify this  "ultralow-risk group" where benefit of endocrine therapy is minimalFor the u...